ALNY vs. RPRX, BMRN, UTHR, IONS, TEVA, GMAB, BGNE, VTRS, SRPT, and RDY
Should you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Ionis Pharmaceuticals (IONS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), BeiGene (BGNE), Viatris (VTRS), Sarepta Therapeutics (SRPT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry.
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends.
Alnylam Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.
Alnylam Pharmaceuticals received 774 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 67.96% of users gave Royalty Pharma an outperform vote.
Royalty Pharma has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Royalty Pharma. MarketBeat recorded 8 mentions for Alnylam Pharmaceuticals and 6 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.02 beat Alnylam Pharmaceuticals' score of 0.33 indicating that Royalty Pharma is being referred to more favorably in the news media.
Alnylam Pharmaceuticals presently has a consensus target price of $216.19, suggesting a potential upside of 44.70%. Royalty Pharma has a consensus target price of $46.75, suggesting a potential upside of 71.43%. Given Royalty Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Royalty Pharma is more favorable than Alnylam Pharmaceuticals.
93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 18.7% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Royalty Pharma has a net margin of 35.70% compared to Alnylam Pharmaceuticals' net margin of -16.58%. Royalty Pharma's return on equity of 22.94% beat Alnylam Pharmaceuticals' return on equity.
Summary
Royalty Pharma beats Alnylam Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Alnylam Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alnylam Pharmaceuticals Competitors List
Related Companies and Tools
